The Use of a Single Dose of Phenobarbital for Inpatient Management of Benzodiazepine Withdrawal: A Case Report.

J Addict Med

From the Harvard Medical School, Boston, MA (JCM); and Division of Addiction Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA (JCM, EH, LV).

Published: March 2023

Introduction: The current standard of care for physiological dependence to benzodiazepines requires prolonged outpatient tapers, which present challenges for patients and providers. Novel protocols for accelerated benzodiazepine tapers are needed. We describe a case of successful management of benzodiazepine withdrawal in the inpatient setting using a single, loading dose of phenobarbital with adjunctive valproate therapy.

Case Report: A 61-year-old woman with benzodiazepine use disorder using 3 to 4 mg of alprazolam daily presented to an inpatient medically supervised withdrawal unit requesting discontinuation of all benzodiazepines and other recreational substances by the time of discharge. Benzodiazepine withdrawal was treated with a single, loading dose of intravenous phenobarbital in line with an approved protocol for the treatment of alcohol withdrawal, as well as adjunctive valproate therapy. The patient experienced resolution of withdrawal symptoms, had no complications, and ongoing abstinence at 60 days of follow-up.

Discussion: A single loading dose of phenobarbital in the inpatient setting is a viable alternative to prolonged outpatient tapers for the management of benzodiazepine withdrawal. Although this strategy requires further optimization, the prospect of a single-dose treatment for benzodiazepine withdrawal creates exciting opportunities for alternative management options and settings.

Conclusions: This case describes the successful management of benzodiazepine withdrawal syndrome using a single loading dose of intravenous phenobarbital derived from an approved protocol for alcohol withdrawal syndrome.

Download full-text PDF

Source
http://dx.doi.org/10.1097/ADM.0000000000001071DOI Listing

Publication Analysis

Top Keywords

benzodiazepine withdrawal
24
management benzodiazepine
16
single loading
16
loading dose
16
dose phenobarbital
12
withdrawal
10
phenobarbital inpatient
8
benzodiazepine
8
prolonged outpatient
8
outpatient tapers
8

Similar Publications

Background: Alcohol abuse leads to millions of hospital admissions each year in the United States. Alcohol withdrawal syndrome (AWS) is associated with several serious complications, including seizures, delirium tremens, and death. Benzodiazepines have been the mainstay of treatment for hospitalized patients with alcohol withdrawal.

View Article and Find Full Text PDF

Phytoceutical Isoquercitrin and Ethanolic Extracts from Pequi (Caryocar coriaceum Wittm) Reverse Alcohol Withdrawal-Induced Anxiety in Adult Zebrafish (Danio rerio).

Behav Brain Res

January 2025

Programa de Pós-Graduação em Nutrição e Saúde (PPGNS), Universidade Estadual do Ceará, CEP 60.741-000, Fortaleza-CE; Laboratório de Bioprospecção de Produtos Naturais e Biotecnologia (LBPNB), Campus CECITEC, CEP 60.660-000, Tauá-CE, Brasil. Electronic address:

Pharmacotherapy in Alcohol Withdrawal Syndrome (AWS), which is a mental disorder, generally involves benzodiazepines due to their action via GABA, but their side effects, such as excessive sedation, mental confusion and risk of dependence, are considerable. It is important to investigate the anxiolytic potential of plants such as Caryocar coriaceum, due to the presence of secondary metabolic compounds, such as isoquercitrin, capable of promoting the reduction of anxiety during AWS. We evaluated the anxiolytic-like potential of ethanolic extracts from the leaves (EEPL) and pulp (EEPP) of C.

View Article and Find Full Text PDF

Introduction: Alcohol withdrawal syndrome (AWS) is a common condition prompting emergency department (ED) presentation. However, there are limited recent, large-scale, robust data available on the incidence, admission, and medical treatment of AWS in the ED.

Methods: This was a retrospective cohort study of ED presentations for AWS from January 1, 2016, to December 31, 2023, using Epic Cosmos.

View Article and Find Full Text PDF

Background: Epilepsy is one of the commonest neurological conditions worldwide and confers a significant mortality risk, partly driven by status epilepticus (SE). Terminating SE is the goal of pharmaceutical rescue therapies. This survey evaluates UK-based healthcare professionals' clinical practice and experience in community-based rescue therapy prescribing.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!